Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2009

View Archived Issues

Centocor Ortho Biotech begins phase I study of psoriasis treatment CNTO-1959

H5N1 influenza virus vaccine from Vaxin induces strong antibody responses in first clinical trial

Human Genome Sciences and GSK report pivotal trial data for Benlysta

FDA accepts for review Spectrum's response on Zevalin as a Class 1 submission

Novel anti Abeta20-42 globulomer antibody, A-887755, under development for AD

Carvedilol shows preclinical potential and enters clinical evaluation for Alzheimer's disease

Novel Raf kinase inhibitors disclosed by the ICR and CRT

Roche presents novel P2X2 and P2X2/3 receptor antagonists

Cardax nominates lead candidate, Heptax, that addresses metabolic syndrome

Novel AMPK activators emerge from Rigel Pharmaceuticals R&D

Nycomed submits NDA to the FDA for Daxas in COPD

Seoul National University and AmorePacific present novel SPC modulators

SeneXta receives FDA IND approval for phase I SNX-001 trial

FDA approves revisions to Erbitux U.S. product labeling in colorectal cancer

Novel angiotensin II receptor blocker R-147176 reduces infarct volume in models of stroke

Respiratory syncytial virus vaccine candidate prevents replication in mouse lungs

FDA to review NDA for APF-530 in chemotherapy-induced nausea and vomiting

Orexigen reports Contrave data from three phase III trials in obesity

AlphaVax completes process development and preclinical studies of their H1N1 vaccine

FDA approves revisions to prescribing information for Amgen's EGFr antibody Vectibix

Evaluation agreement for the development and commercialization of TPR-100

Ardea commences phase IIb trial of RDEA-594 for gout

INNO-206 shown to inhibit pancreatic cancer growth in animal trials

Data reported from DURATION-3 trial comparing exenatide to Lantus in diabetes

Data Monitoring Committee reviews phase III Hematide program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...